BioProbe-PIT
Financiado
Local molecular profiling of tumor tissue sections towards personalized immunot...
Cancer heterogeneity has reinforced the need for personalized treatment modalities. Pre-therapeutic diagnostic testing of heterogeneous tumors helps avoid inefficacious treatments, optimizes targeted therapy, and improves quality...
Cancer heterogeneity has reinforced the need for personalized treatment modalities. Pre-therapeutic diagnostic testing of heterogeneous tumors helps avoid inefficacious treatments, optimizes targeted therapy, and improves quality of life. Within targeted therapy, immunotherapy has led to significant improvements in treatment outcomes and is swiftly being integrated in diagnostic workflows. In this context, routine diagnostic tests currently do not exist, and treatments are further challenged by heterogeneity. Spatially resolved molecular probing of tumors prior to treatment would allow prediction of patient response to immunotherapeutics.
We have been developing methods to perform local biochemical reactions at micrometer length scales using nanoliter volumes of biochemicals. These methods are implemented using a scanning probe technology – the microfluidic probe (MFP) – with devices, platforms and assays adapted for application on biological substrates. With this, we are working towards multi-modal molecular profiling of tumors – tissue microprocessing (TMP). Thus far, we have demonstrated TMP for local DNA and mRNA analysis on live cells, for patterning cells and for micro-immunohistochemical tests on tissues.
Here, we will leverage TMP concepts to work on the initial steps in pre-commercializing the MFP for diagnostic testing in immunotherapy. Specifically, we aim to
(1) develop assays for morphological and molecular analyses of pancreatic tissues using the MFP
(2) adapt the assays developed in (1) to be compatible with workflows of state-of-the-art genome and transcriptome analysis for molecular profiling of tumors in diagnostics
(3) validate these techniques for patient samples.
With this PoC grant, we envision to translate the MFP technology from the lab to the clinic for personalized immunotherapy.
ver más
Duración del proyecto: 12 meses
Fecha Inicio: 2017-07-25
Fecha Fin: 2018-07-31
Fecha Fin: 2018-07-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-07-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-PoC-2016:
ERC-Proof of Concept-2016
Cerrada
hace 8 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
IBM RESEARCH GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
494.99K€ |
Participante